Vagus nerve stimulation: can it be used in adolescents or children with treatment-resistant depression?
Vagus nerve stimulation (VNS) therapy has been approved by the US Food and Drug Administration for treatment-resistant depression in patients 18 years of age and older and for intractable epilepsy. Long-term studies suggest VNS has an antidepressant effect in adults. This paper reviews the available clinical data for VNS therapy. Its potential application for treatment-resistant depression in adolescents and children is also discussed.
Yu
Zheya Jenny
ZJ
Children's Hospital of Philadelphia, 3440 Market Street, Philadelphia, PA 19104, USA. yuz@email.chop.edu
Weller
Ronald A
RA
Sandidge
Kendra
K
Weller
Elizabeth B
EB
D000293:Adolescent; D000328:Adult; D000344:Afferent Pathways / Q000503:physiopathology; D000818:Animals; D001921:Brain / Q000503:physiopathology; D002648:Child; D015928:Cognitive Behavioral Therapy; D003866:Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D004599:Electric Stimulation Therapy / Q000009:adverse effects / Q000295:instrumentation; D006801:Humans; D010555:Personality Inventory; D019736:Prostheses and Implants; D011613:Psychotherapy; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D014630:Vagus Nerve / Q000503:physiopathology*